Deadline: 19-Nov-21
Nominations are now open for the RIGHT Fund Product Development Award to develop health-related technologies at or near the clinical development or validation phase, with a path to impact on public health and health equity globally.
The RIGHT Fund was established as a partnership between the Korean government, pharmaceutical companies, and the Bill & Melinda Gates Foundation (BMGF) with the Government of Korea as the largest funder. The partnership strives to deliver innovative technologies to prevent and control infectious diseases that are of a global concern particularly in low-resource settings.
Collaborations between investigators are a crucial component of the proposals and applicants should outline a concrete framework for the collaboration between partners, as well as articulate how the proposed collaboration would enable a path to impact on public health and health equity between and within countries. The grant will be managed by the RIGHT Fund with payment contingencies well-coordinated to ensure that key milestones are met, and that the collaborative nature of each grant is maintained.
Focus areas and Development stages
- Three main focus areas: New approaches or constructs, improvement of products or data systems, equitable access
- Development stages:
- Therapeutics and Vaccines: Projects at clinical development stages (i.e., Phase I and onward)
- Diagnostics and Digital Health: Projects for which the proof of principle have been successfully demonstrated and are near or at clinical validation and/or development phase (i.e., development phase and beyond).
Funding Information
- Target diseases: Infectious diseases endemic and emerging in LMICs
- Technology Interventions: Vaccines, Therapeutics, Diagnostics, and Digital Health
- Award amount: RIGHT Fund will invest up to 50% of total project cost up to 4 billion Korean won (approximately equivalent to US$ 4 million) per project over the funding period
- Project duration: The duration of the funding is up to 3 years (36 months).
Eligibility Criteria
- Partnerships shall include at least one Korean entity with a capacity of health intervention R&D and the expertise to identify projects that represent substantial additions to the field.
- Applicants must accept the Global Access Policy of the RIGHT Fund.
- The RIGHT Fund will invest up to 50% of the total project cost over the funding period and applicants must provide a plan to secure full funding to complete the project.
- The RIGHT Fund reserves the right to determine eligibility of applicants and public health priority among proposals at its discretion
For more information, visit https://rightfund.org/en/apply-for-funding/product-development-award/pda-instructions/
